IGT'S NEW CANCER DRUG, ANHYDROVINBLASTINE, PRESENTED AT THE 89TH
ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH
VANCOUVER, May 7 /CNW/ - IGT Pharma Inc.
VSE Trading Symbol: IGT
A poster presentation featuring the unique therapeutic profile of the new
cancer drug, Anhydrovinblastine (AVLB) was made at the 89th Annual Meeting of
the American Association for Cancer Research in New Orleans, April 1, 1998.
Pre-clinical studies conducted at the B.C. Cancer Agency in Vancouver
using Anhydrovinblastine (AVLB), IGT's patented anti-cancer drug, have shown
excellent preliminary results in reducing tumors relating to human lung cancer
and human cervical cancer.
In a twenty three day comparative ''in vivo'' study it was found that
lung cancer tumors of human origin implanted and grown in SCID/Rag-2 mice and
subsequently treated with AVLB were 7 times smaller than those treated with
Navelbine(TM), Glaxo's approved anti-cancer drug.
In another similar study, it was found that AVLB was able to delay the
growth of human cervical cancer tumors in mice for the entire duration of the
study and, 20 days after administration of the drug, the tumors were
essentially too small to be accurately measured. At the end of the 75 day
study, the tumors treated by AVLB remained smaller than at the commencement of
the study and were 10 times smaller than those treated with Navelbine(TM).
The study further concluded that AVLB had less drug associated toxicity
than Navelbine(TM), thus further enhancing its therapeutic profile.
Currently, the Investigational New Drug Application (IND) is being
prepared for submission to the regulatory authorities and Phase 1 human
clinical trials are scheduled to begin in the summer of this year at the B.C.
Cancer Agency.
IGT Pharma Inc. is a Vancouver based bio-pharmaceutical company focused
on the evolution of synthetic chemistry to provide new drug therapies to the
major oncology and neurology markets. Its subsidiary, Precision Biochemicals
Inc., is an established supplier of custom chemicals and contract
manufacturing, to the North American chemical and pharmaceutical markets.
On behalf of the board of directors of IGT Pharma Inc.
per: Bruce Schmidt, President
The Vancouver Stock Exchange has not reviewed and does not accept
responsibility for the accuracy of this News Release.
-30-
For further information: Bruce Schmidt, President (604) 822-3503 or
1-800-743-7444 or Web Site: igtpharma.com
IGT PHARMA INC. has 1 releases in this database.
General Inquiries cnw@newswire.ca
Technical Issues webmaster@newswire.ca
|
